Medical - Diagnostics & Research
Build Your Comparison
Side-by-side financial analysisStock Comparison
BLLN vs PGNY
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
BLLN vs PGNY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Healthcare Information Services |
| Market Cap | $4.65B | $2.09B |
| Revenue (TTM) | $355M | $1.29B |
| Net Income (TTM) | $25M | $68M |
| Gross Margin | 70.4% | 24.1% |
| Operating Margin | 10.2% | 7.5% |
| Forward P/E | 102.7x | 20.8x |
| Total Debt | $109M | $24M |
| Cash & Equiv. | $496M | $112M |
Quick Verdict: BLLN vs PGNY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BLLN is the clearest fit if your priority is growth exposure.
- Rev growth 100.0%, EPS growth 106.8%
- 100.0% revenue growth vs PGNY's 10.4%
- 7.1% margin vs PGNY's 5.2%
PGNY carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.61
- 67.1% 10Y total return vs BLLN's -7.2%
- Lower volatility, beta 0.61, Low D/E 4.7%, current ratio 2.73x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 100.0% revenue growth vs PGNY's 10.4% | |
| Value | Lower P/E (20.8x vs 102.7x) | |
| Quality / Margins | 7.1% margin vs PGNY's 5.2% | |
| Stability / Safety | Beta 0.61 vs BLLN's 1.91, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +23.6% vs BLLN's -7.2% | |
| Efficiency (ROA) | 9.0% ROA vs BLLN's 5.1%, ROIC 18.1% vs 13.5% |
BLLN vs PGNY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BLLN vs PGNY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
BLLN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PGNY is the larger business by revenue, generating $1.3B annually — 3.6x BLLN's $355M. Profitability is closely matched — net margins range from 7.1% (BLLN) to 5.2% (PGNY). On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $355M | $1.3B |
| EBITDAEarnings before interest/tax | $44M | $100M |
| Net IncomeAfter-tax profit | $25M | $68M |
| Free Cash FlowCash after capex | $28M | $181M |
| Gross MarginGross profit ÷ Revenue | +70.4% | +24.1% |
| Operating MarginEBIT ÷ Revenue | +10.2% | +7.5% |
| Net MarginNet income ÷ Revenue | +7.1% | +5.2% |
| FCF MarginFCF ÷ Revenue | +7.9% | +14.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +83.8% | +1.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +4.8% | +70.6% |
Valuation Metrics
PGNY leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 41.0x trailing earnings, PGNY trades at a 97% valuation discount to BLLN's 1587.4x P/E. On an enterprise value basis, PGNY's 22.1x EV/EBITDA is more attractive than BLLN's 266.1x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $4.7B | $2.1B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | 1587.44x | 40.97x |
| Forward P/EPrice ÷ next-FY EPS est. | 102.72x | 20.82x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.12x |
| EV / EBITDAEnterprise value multiple | 266.12x | 22.14x |
| Price / SalesMarket cap ÷ Revenue | 15.24x | 1.62x |
| Price / BookPrice ÷ Book value/share | 9.65x | 4.62x |
| Price / FCFMarket cap ÷ FCF | 295.98x | 10.88x |
Profitability & Efficiency
PGNY leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
PGNY delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $8 for BLLN. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to BLLN's 0.23x. On the Piotroski fundamental quality scale (0–9), BLLN scores 7/9 vs PGNY's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +7.6% | +13.3% |
| ROA (TTM)Return on assets | +5.1% | +9.0% |
| ROICReturn on invested capital | +13.5% | +18.1% |
| ROCEReturn on capital employed | +3.7% | +17.4% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.23x | 0.05x |
| Net DebtTotal debt minus cash | -$387M | -$88M |
| Cash & Equiv.Liquid assets | $496M | $112M |
| Total DebtShort + long-term debt | $109M | $24M |
| Interest CoverageEBIT ÷ Interest expense | 516.43x | — |
Total Returns (Dividends Reinvested)
BLLN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLLN five years ago would be worth $9,282 today (with dividends reinvested), compared to $4,131 for PGNY. Over the past 12 months, PGNY leads with a +23.6% total return vs BLLN's -7.2%. The 3-year compound annual growth rate (CAGR) favors BLLN at -2.5% vs PGNY's -12.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +13.2% | +3.5% |
| 1-Year ReturnPast 12 months | -7.2% | +23.6% |
| 3-Year ReturnCumulative with dividends | -7.2% | -32.6% |
| 5-Year ReturnCumulative with dividends | -7.2% | -58.7% |
| 10-Year ReturnCumulative with dividends | -7.2% | +67.1% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -12.3% |
Risk & Volatility
PGNY leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PGNY is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PGNY currently trades 92.6% from its 52-week high vs BLLN's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 0.61x |
| 52-Week HighHighest price in past year | $138.70 | $28.75 |
| 52-Week LowLowest price in past year | $61.96 | $16.10 |
| % of 52W HighCurrent price vs 52-week peak | +72.9% | +92.6% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 64.6 |
| Avg Volume (50D)Average daily shares traded | 642K | 1.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BLLN as "Buy" and PGNY as "Buy". Consensus price targets imply 23.6% upside for BLLN (target: $125) vs 13.9% for PGNY (target: $30).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $125.00 | $30.33 |
| # AnalystsCovering analysts | 4 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.9% |
PGNY leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). BLLN leads in 2 (Income & Cash Flow, Total Returns).
BLLN vs PGNY: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is BLLN or PGNY a better buy right now?
For growth investors, BillionToOne, Inc.
(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 10. 4% for Progyny, Inc. (PGNY). Progyny, Inc. (PGNY) offers the better valuation at 41. 0x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BLLN or PGNY?
On trailing P/E, Progyny, Inc.
(PGNY) is the cheapest at 41. 0x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, Progyny, Inc. is actually cheaper at 20. 8x.
03Which is the better long-term investment — BLLN or PGNY?
Over the past 5 years, BillionToOne, Inc.
(BLLN) delivered a total return of -7. 2%, compared to -58. 7% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: PGNY returned +67. 1% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BLLN or PGNY?
By beta (market sensitivity over 5 years), Progyny, Inc.
(PGNY) is the lower-risk stock at 0. 61β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately 214% more volatile than PGNY relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 23% for BillionToOne, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BLLN or PGNY?
By revenue growth (latest reported year), BillionToOne, Inc.
(BLLN) is pulling ahead at 100. 0% versus 10. 4% for Progyny, Inc. (PGNY). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to 14. 0% for Progyny, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BLLN or PGNY?
Progyny, Inc.
(PGNY) is the more profitable company, earning 4. 5% net margin versus 2. 4% for BillionToOne, Inc. — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 5. 3% for BLLN. At the gross margin level — before operating expenses — BLLN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BLLN or PGNY more undervalued right now?
On forward earnings alone, Progyny, Inc.
(PGNY) trades at 20. 8x forward P/E versus 102. 7x for BillionToOne, Inc. — 81. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLLN: 23. 6% to $125. 00.
08Which pays a better dividend — BLLN or PGNY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is BLLN or PGNY better for a retirement portfolio?
For long-horizon retirement investors, Progyny, Inc.
(PGNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PGNY: +67. 1%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BLLN and PGNY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BLLN is a small-cap high-growth stock; PGNY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.